82 related articles for article (PubMed ID: 21428246)
1. Physicochemical and toxicological characterization of a new generic iron sucrose preparation.
Meier T; Schropp P; Pater C; Leoni AL; Khov-Tran VV; Elford P
Arzneimittelforschung; 2011; 61(2):112-9. PubMed ID: 21428246
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
3. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
8. Particle Size, Surface Area, and Amorphous Content as Predictors of Solubility and Bioavailability for Five Commercial Sources of Ferric Orthophosphate in Ready-To-Eat Cereal.
Dickmann RS; Strasburg GM; Romsos DR; Wilson LA; Lai GH; Huang H
Nutrients; 2016 Mar; 8(3):129. PubMed ID: 26938556
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells.
Roth S; Langguth P; Spicher K; Enzmann H
Transl Res; 2008 Jan; 151(1):36-44. PubMed ID: 18061126
[TBL] [Abstract][Full Text] [Related]
10. Short-term stability of a new generic sodium ferric gluconate in complex with sucrose.
Baribeault D
Curr Med Res Opin; 2011 Dec; 27(12):2241-3. PubMed ID: 21992082
[TBL] [Abstract][Full Text] [Related]
11. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
13. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
Krafft A; Breymann C
J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
[TBL] [Abstract][Full Text] [Related]
14. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
16. Iron sucrose: the oldest iron therapy becomes new.
Yee J; Besarab A
Am J Kidney Dis; 2002 Dec; 40(6):1111-21. PubMed ID: 12460028
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
